Novo Nordisk and Amazon Web Services (AWS) announced a strategic partnership on August 10, 2026, to accelerate drug discovery and modernize Novo Nordisk's operations through agentic artificial intelligence (AI) and cloud technologies.1 The agreement names AWS as Novo Nordisk's preferred cloud provider and strategic AI partner, and the companies have opened a co-innovation hub in London where AWS engineers and AI specialists will work alongside Novo Nordisk research and development teams to shorten the path from drug target to first human dose.1
Key facts
- Companies: Novo Nordisk; Amazon Web Services (AWS)
- Partnership type: Strategic AI and cloud collaboration
- Key initiative: AI co-innovation hub (London)
- AI tools: Amazon Bio Discovery, Amazon Bedrock, Bedrock AgentCore
- Cloud status: AWS named preferred cloud provider
- Existing results: Reduced clinical documentation time; 25,000+ employees using AI tools
- Broader AI portfolio: OpenAI partnership (April 2026)
- Company scale: ~66,700 employees; 80 countries (Novo Nordisk)
- Announcement date: August 10, 2026
- Geography: Global partnership; hub based in London
"Partnering with AWS is about making AI a driver of innovation across Novo Nordisk," said Mike Doustdar, president and CEO of Novo Nordisk, in a company press release.1
"Every part of our work with Novo Nordisk comes back to one thing: getting the right medicine to patients, faster," added Matt Garman, CEO of AWS, in the release.1
What will the partnership actually do?
Under the agreement, Novo Nordisk will use AWS services including Amazon Bio Discovery and Amazon Bedrock to identify drug targets, design new therapies, and connect genomic, imaging, and clinical data so that early research findings can shape clinical trial design. The company will also apply Amazon Bedrock AgentCore, an AI agent platform, to drive efficiencies across its broader operations. As part of the collaboration, AWS will provide forward deployed engineers to work directly alongside Novo Nordisk's science teams to help process complex datasets and scale findings across therapeutic areas.1
What results has the companies' existing collaboration already produced?
Novo Nordisk said its work with AWS has already reduced clinical documentation time and helped more than 25,000 employees boost productivity, and the new agreement builds on that longstanding relationship.1 The company said it will also continue collaborating with other Amazon businesses, including Amazon Pharmacy, Amazon Ads, and Amazon One Medical, to change how new therapies are marketed and delivered to patients.1
How does this fit into Novo Nordisk's broader AI strategy?
The AWS deal follows Novo Nordisk's April 2026 strategic partnership with OpenAI, which will integrate OpenAI's AI capabilities across drug discovery, manufacturing, supply chain, and commercial operations, with full integration targeted by the end of 2026.2 The AWS partnership adds cloud infrastructure and life sciences-specific AI tools to that expanding AI portfolio, as pharmaceutical companies increasingly compete on AI-driven drug development timelines.2
What are the limitations?
The companies did not disclose the financial terms of the partnership or specific timelines for when AI-assisted programs might translate into new therapies reaching patients. As with other pharma AI partnerships, measurable drug-development outcomes from the collaboration may take years to materialize.
References
1. Novo Nordisk. Novo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI. Press release. Published August 10, 2026. Accessed August 10, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916594
2. Novo Nordisk. Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered. Press release. Published April 14, 2026. Accessed August 10, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916532
